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Background: CMV disease remains an important cause of morbidity after kidney 
transplantation and has been associated with graft loss and other indirect effects. A 3-month 
course of VGC prophylaxis reduces the incidence of CMV disease. However, little is known 
about the indirect effects of late-onset CMV disease after VGC prophylaxis. 
Objective: To evaluate the impact and indirect consequences of late-onset CMV disease 
after VGC prophylaxis in kidney transplant recipients. 
Methods: Retrospective analysis of 61 consecutive adult kidney transplant recipient with 
positive CMV serology (donor or recipient) who received VGC prophylaxis for 3 months and 
completed a follow-up of at least 2 years post-transplantation. Patients who developed CMV 
disease were compared to CMV disease-free patients for renal function (plasma creatinine 
values) at 1, 6, 12 and 24 months and for the incidence of graft loss, acute rejection, diabetes, 
cancer and opportunistic infections.  
Results: 8/61 (13%) patients developed CMV disease at a median of 131 days after 
transplantation (range: 98 – 220). The CMV incidence in D+/R- high risk patients was 6/18 
(33%), while it was 2/43 (5%) in intermediate-risk patients (p < 0.01). All 8 patients were 
treated by oral valganciclovir (median 39 days; range: 19 – 119) with a complete resolution of 
CMV disease. There was no difference in creatinine values between the two groups at any 
time during follow-up (Figure). There was no graft loss, and the incidence of acute rejection, 
cancer and opportunistic infections did not differ between the two group. The incidence of 
post-transplant diabetes was higher (38% vs 15%) in patients with CMV disease, but this 
difference was not significant (p = 0.4).   
Conclusions: An incidence of 13% of late-onset CMV disease was observed despite 3 months VGC 
prophylaxis. However, no indirect consequences were found. Moreover, therapy of CMV disease 
by oral VGC was effective and safe. Larger trials are needed to study whether late-onset CMV 
disease is associated with indirect consequences, as described with early-onset CMV.  
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